The Chemours Company CC
13.48 USD +0.20 (+1.51%)
At closeNov 11, 2026, 4:00 AM EST
14.74 +1.26 +9.31%
Pre-market · Nov 11, 4:00 AM ET
12.79 Day range 13.58
10.44 52-week range 28.67
- YTD
- +14.33%
- 1 year
- +5.73%
Benzinga news
benzinga.com JP Morgan Maintains Neutral on Chemours, Lowers Price Target to $14 JP Morgan analyst Jeffrey Zekauskas maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $15 to $14.
benzinga.com UBS Maintains Neutral on Chemours, Lowers Price Target to $15 UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $16 to $15.- benzinga.com Truist Securities Maintains Buy on Chemours, Lowers Price Target to $18 Truist Securities analyst Peter Osterland maintains Chemours (NYSE:CC) with a Buy and lowers the price target from $20 to $18.
benzinga.com Chemours Q3 2026 Earnings Call Transcript Chemours (NYSE:CC) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Chemours Narrows FY2026 Sales Guidance from $5.866B-$6.098B to $5.924B vs $5.917B Est Chemours (NYSE:CC) narrows FY2026 sales outlook from $5.866 billion-$6.098 billion to $5.924 billion vs $5.917 billion estimate.
benzinga.com Chemours Q3 Adj. EPS $0.21 Misses $0.27 Estimate, Sales $1.540B Inline Chemours (NYSE:CC) reported quarterly earnings of $0.21 per share which missed the analyst consensus estimate of $0.27 by 22.22 percent. This is a 5 percent increase over earnings of $0.20 per share…- benzinga.com Truist Securities Maintains Buy on Chemours, Lowers Price Target to $20 Truist Securities analyst Peter Osterland maintains Chemours (NYSE:CC) with a Buy and lowers the price target from $24 to $20.
benzinga.com This Chemours Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday Analysts downgraded CTNM, CC, ACI, BRKR and SAFE; targets fell for CTNM, CC and ACI, while BRKR received a new $60 target.
benzinga.com Mizuho Downgrades Chemours to Neutral, Lowers Price Target to $15 Mizuho analyst John Roberts downgrades Chemours (NYSE:CC) from Outperform to Neutral and lowers the price target from $18 to $15.
benzinga.com Barclays Initiates Coverage On Chemours with Equal-Weight Rating, Announces Price Target of $16 Barclays analyst Aleksey Yefremov initiates coverage on Chemours (NYSE:CC) with a Equal-Weight rating and announces Price Target of $16.